Lymphocyte Gene Therapy
- 1 July 1991
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 2 (2) , 107-109
- https://doi.org/10.1089/hum.1991.2.2-107
Abstract
Genetically corrected T cells are currently under investigation as a treatment for severe combined immunodeficiency disease resulting from a lack of adenosine deaminase (ADA). Monthly injections of these ADA-corrected T cells have resulted in measurable ADA activity in the peripheral blood and the in vivo production of antibody to blood group antigen. Genetically corrected T cells appear to be clinically valuable vehicles for gene therapy.Keywords
This publication has 9 references indexed in Scilit:
- Lymphocytes as cellular vehicles for gene therapy in mouse and man.Proceedings of the National Academy of Sciences, 1991
- An in Vivo Model of Somatic Cell Gene Therapy for Human Severe Combined ImmunodeficiencyScience, 1991
- In VivoExpression and Survival of Gene-Modified T Lymphocytes in Rhesus MonkeysHuman Gene Therapy, 1990
- Expression of Introduced Genetic Sequences in Hematopoietic Cells Following Retroviral-Mediated Gene TransferHuman Gene Therapy, 1990
- Points to Consider Response with Clinical Protocol, July 6, 1990Human Gene Therapy, 1990
- Tolerance of engrafted donor T cells following bone marrow transplantation for severe combined immunodeficiencyClinical Immunology and Immunopathology, 1988
- Adenosine deaminase deficiency with late onset of recurrent infections: Response to treatment with polyethylene glycol-modified adenosine deaminaseThe Journal of Pediatrics, 1988
- Treatment of Adenosine Deaminase Deficiency with Polyethylene Glycol–Modified Adenosine DeaminaseNew England Journal of Medicine, 1987
- ADENOSINE-DEAMINASE DEFICIENCY IN TWO PATIENTS WITH SEVERELY IMPAIRED CELLULAR IMMUNITYThe Lancet, 1972